* A new nonnucleoside reverse-transcriptase inhibitor (NNRTI), rilpivirine (Edurant), has been approved for the treatment of HIV and AIDS.
* Patients with an excessively high viral load shouldn't start taking rilpivirine because it will increase their risk of treatment failure; also, patients who've experienced treatment failure are more likely to develop resistance to other NNRTIs.
* Rilpivirine should be taken with a meal for maximum absorption.
Diane S. Aschenbrenner is the course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch: email@example.com.